Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent ...
Read more